OCT 03, 2014 12:00 AM PDT

More Than 700 Biosimilar Therapies in Pipelines

WRITTEN BY: Ilene Schneider
It is rare to see a new business segment emerge in any market, but this is what is happening within the biopharmaceutical development industry, according to a new report from Thomson Reuters BioWorld, the premier biopharmaceutical news service.

There are currently 700 follow-on biologics therapies moving through pipelines with many already approved and 245 biopharma companies and institutes developing or already marketing follow-on biologics in markets throughout the world. Biosimilars are expected to account for approximately one quarter of the $100 billion worth of sales stemming from off-patent biologics by the end of the decade, the report said.

South Korea is a notable standout in the race for global leadership in this space, and India anticipates biosimilars becoming the most important economic and therapeutic component of its already robust biopharma industry. The study-the culmination of BioWorld's research combined with key data and insights gathered from CortellisTM Competitive Intelligence and input from Thomson Reuters Life Sciences Professional Services, provides a comprehensive view of this emerging market with a listing of approved biosimilars, company and deal terms for more than 100 alliances, and an examination of global markets.

Key highlights from the report include:
* Big pharma and generics makers face a steep learning curve: While generic makers currently lead the pack, the expertise in this market is held by the biologics makers. New pure-play biosimilar makers funded by governments and private investors also have a strong presence in this arena.

* Biosimilars promise to deliver big savings: Typically offering 20 to 30 percent discounts from innovator biologics, biosimilars are expected to deliver $11 billion to $33 billion in savings across the European Union (EU) by 2020.

* Opportunities for smaller players: Start-ups working to make and sell biosimilars in emerging territories could be the "David" ticket to beat pharma "Goliaths" that dominate those realms.

* Lower-prices: Slow market uptake of biosimilars in the EU may not also hold true for the U.S. Unlike most of the EU, the U.S. will allow interchangeability, which is expected to speed adoption and lead to lower prices.

* A level playing field: The World Health Organization recently proposed a voluntary, global naming scheme that could level the playing field for biosimilars and their reference biologics.

* Accessible treatment: In many parts of the world, follow-ons offer new hope to patients who previously did not have access to pricey biologics, bringing the power of biologics for the first time to markets in Africa, Asia, Eastern Europe and Latin America.

"Rather than forgo the benefits of biologics, governments and payers are counting on biosimilars to dramatically change drug development and patient costs by reducing the price tag of important biologics and increasing access to life-saving drugs," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences. "For this to happen, biosimilars must deliver the power of the reference drugs at a price developing countries can afford and gain the confidence of the marketplace. They have to create their own market."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 22, 2020
APR 22, 2020
First COVID-19 Death Happened in the US Far Earlier Than We Thought
It was thought that the first death in the US from SARS-CoV-2 happened in Washington State in late February, but autopsi ...
APR 23, 2020
Clinical & Molecular DX
APR 23, 2020
FDA Approves At-Home Sample Collection Diagnostic Test for COVID-19
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). M ...
MAY 07, 2020
Clinical & Molecular DX
MAY 07, 2020
An 8 Minute DNA Test For Salmonella
Australian researchers have created a sensitive, super-fast test for five different serotypes of Salmonella which could ...
MAY 14, 2020
Chemistry & Physics
MAY 14, 2020
Do Organic Chemists Speak an Alien Language?
Have you ever read a detergent label and got confused? Or had trouble understanding a medication recall? Certain ch ...
MAY 15, 2020
MAY 15, 2020
Support the Microbiome So the Immune System Can Do Its Job
Research has long connected the human microbiome and immune system function, and now a recent study pinpoints a key poin ...
MAY 22, 2020
Genetics & Genomics
MAY 22, 2020
ALK - The Skinny Gene?
Some people have to count calories and exercise regularly to be skinny while others can consume whatever they want and n ...
Loading Comments...